Gilead poaches oncology expert Quigley from BMSGilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of Share XGilead poaches oncology expert Quigley from BMShttps://pharmaphorum.com/news/gilead-poaches-oncology-expert-quigley-from-bms/
FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
Calibr and AbbVie’s switchable cancer CAR-T begins clinical trialsCalifornia biotech Calibr and research partner AbbVie have clearance to start clinical trials of a new CAR-T technology, Share XCalibr and AbbVie’s switchable cancer CAR-T begins clinical trialshttps://pharmaphorum.com/news/calibr/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
BMS files first drug from triple bet with Celgene shareholders with FDABristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” Share XBMS files first drug from triple bet with Celgene shareholders with FDAhttps://pharmaphorum.com/news/bms-files-first-drug-from-triple-bet-with-celgene-shareholders-with-fda/
Gilead to file new CAR-T, setting up potential mid-2020 launchGilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing Share XGilead to file new CAR-T, setting up potential mid-2020 launchhttps://pharmaphorum.com/news/gilead-to-file-new-car-t/
Understanding the evolving CAR-T marketIn August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor Share XUnderstanding the evolving CAR-T markethttps://pharmaphorum.com/partner-content/understanding-the-evolving-car-t-market/
Q&A: Draper’s Jenna Balestrini on the future of CAR-TAs exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential. Jenna Share XQ&A: Draper’s Jenna Balestrini on the future of CAR-Thttps://pharmaphorum.com/views-analysis-oncology/qa-drapers-jenna-balestrini-on-the-future-of-car-t/
CAR-TCR Summit EuropeEngineering A Cancer-Free World Share XCAR-TCR Summit Europehttps://pharmaphorum.com/events/car-tcr-summit-europe/
